title: Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disrupters.
abstract: Polyhalogenated aromatic hydrocarbons (PHAHs), such as polychlorinated dibenzo-p-dioxins and dibenzofurans, polybrominated diphenylethers, and bisphenol A derivatives are persistent environmental pollutants, which are capable of interfering with reproductive and endocrine function in birds, fish, reptiles, and mammals. PHAHs exert estrogenic effects that may be mediated in part by their hydroxylated metabolites (PHAH-OHs), the mechanisms of which remain to be identified. PHAH-OHs show low affinity for the ER. Alternatively, they may exert their estrogenic effects by inhibiting E2 metabolism. As sulfation of E2 by estrogen sulfotransferase (SULT1E1) is an important pathway for E2 inactivation, inhibition of SULT1E1 may lead to an increased bioavailability of estrogens in tissues expressing this enzyme. Therefore, we studied the possible inhibition of human SULT1E1 by hydroxylated PHAH metabolites and the sulfation of the different compounds by SULT1E1. We found marked inhibition of SULT1E1 by various PHAH-OHs, in particular by compounds with two adjacent halogen substituents around the hydroxyl group that were effective at (sub)nanomolar concentrations. Depending on the structure, the inhibition is primarily competitive or noncompetitive. Most PHAH-OHs are also sulfated by SULT1E1. We also investigated the inhibitory effects of the various PHAH-OHs on E2 sulfation by human liver cytosol and found that the effects were strongly correlated with their inhibitions of recombinant SULT1E1 (r = 0.922). Based on these results, we hypothesize that hydroxylated PHAHs exert their estrogenic effects at least in part by inhibiting SULT1E1-catalyzed E2 sulfation.
authors.affiliation: Department of Internal Medicine, Erasmus University Medical Center, 3015 GJ Rotterdam, The Netherlands.
authors.forename: Monique H A
authors.initials: MH
authors.lastname: Kester
authors.forename: Sema
authors.initials: S
authors.lastname: Bulduk
authors.forename: Hans
authors.initials: H
authors.lastname: van Toor
authors.forename: Dick
authors.initials: D
authors.lastname: Tibboel
authors.forename: Walter
authors.initials: W
authors.lastname: Meinl
authors.forename: Hansruedi
authors.initials: H
authors.lastname: Glatt
authors.forename: Charles N
authors.initials: CN
authors.lastname: Falany
authors.forename: Michael W H
authors.initials: MW
authors.lastname: Coughtrie
authors.forename: A Gerlienke
authors.initials: AG
authors.lastname: Schuur
authors.forename: Abraham
authors.initials: A
authors.lastname: Brouwer
authors.forename: Theo J
authors.initials: TJ
authors.lastname: Visser
mesh_terms: D003600:Cytosol / Q000378:metabolism; D004700:Endocrine System Diseases / Q000209:etiology*; D004958:Estradiol / Q000378:metabolism*; D006801:Humans; D006846:Hydrocarbons, Halogenated / Q000737:chemistry / Q000378:metabolism*; D006900:Hydroxylation; D066298:In Vitro Techniques; D008099:Liver / Q000378:metabolism; D013431:Sulfates / Q000378:metabolism; D015238:Sulfotransferases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D006846:Hydrocarbons, Halogenated; D013431:Sulfates; D004958:Estradiol; D015238:Sulfotransferases; C020122:estrone sulfotransferase